scholarly journals Monoclonal antibody--specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies

Blood ◽  
1987 ◽  
Vol 70 (6) ◽  
pp. 1722-1726 ◽  
Author(s):  
V Kiefel ◽  
S Santoso ◽  
M Weisheit ◽  
C Mueller-Eckhardt
Keyword(s):  
Monoclonal Antibody ◽  
Monoclonal Antibodies ◽  
Hla Class I ◽  
Platelet Membrane ◽  
Class I ◽  
Hla Antibodies

Abstract The analysis of sera containing different platelet-reactive antibodies, eg, autoantibodies, platelet-specific alloantibodies like anti-PIA1, - PIA2, -Baka, and HLA antibodies, is still difficult. Recently, monoclonal antibodies against major platelet membrane constituents (glycoproteins IIb/IIIa and Ib and HLA class I molecule) have become available. In this report we describe a new assay that takes advantage of these highly specific reagents to investigate selectively platelet reactive antibodies against epitopes on different glycoproteins. The reliability and specificity of this assay is demonstrated with known platelet-reactive autoantibodies and alloantibodies (anti-PIA1, -Baka, - Pen). The discovery of a PIA2 antibody in a serum of a polytransfused patient underscores the efficiency of this technique. Possible applications of this assay are discussed in detail.

scholarly journals Monoclonal antibody--specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies

Blood ◽  
1987 ◽  
Vol 70 (6) ◽  
pp. 1722-1726 ◽  
Author(s):  
V Kiefel ◽  
S Santoso ◽  
M Weisheit ◽  
C Mueller-Eckhardt
Keyword(s):  
Monoclonal Antibody ◽  
Monoclonal Antibodies ◽  
Hla Class I ◽  
Platelet Membrane ◽  
Class I ◽  
Hla Antibodies

The analysis of sera containing different platelet-reactive antibodies, eg, autoantibodies, platelet-specific alloantibodies like anti-PIA1, - PIA2, -Baka, and HLA antibodies, is still difficult. Recently, monoclonal antibodies against major platelet membrane constituents (glycoproteins IIb/IIIa and Ib and HLA class I molecule) have become available. In this report we describe a new assay that takes advantage of these highly specific reagents to investigate selectively platelet reactive antibodies against epitopes on different glycoproteins. The reliability and specificity of this assay is demonstrated with known platelet-reactive autoantibodies and alloantibodies (anti-PIA1, -Baka, - Pen). The discovery of a PIA2 antibody in a serum of a polytransfused patient underscores the efficiency of this technique. Possible applications of this assay are discussed in detail.

ADSORPTION OF CYTOTOXIC ANTI-HLA ANTIBODIES WITH HLA CLASS I IMMUNOSORBANT BEADS

1990 ◽  
Vol 49 (5) ◽  
pp. 925-930 ◽  
Author(s):  
LYNN D. DEVITO ◽  
HANS W. SOLLINGER ◽  
WILLIAM J. BURLINGHAM
Keyword(s):  
Hla Class I ◽  
Class I ◽  
Hla Antibodies

Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules

2003 ◽  
Vol 64 (3) ◽  
pp. 315-326 ◽  
Author(s):  
Catherine Menier ◽  
Berta Saez ◽  
Vaclav Horejsi ◽  
Silvia Martinozzi ◽  
Irene Krawice-Radanne ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Hla Class I ◽  
Class I ◽  
Hla Class I Molecules

Reactivity of Anti-HLA Class I Polymorphic Monoclonal Antibodies with Normal Human Skin

Hybridoma ◽  
1987 ◽  
Vol 6 (5) ◽  
pp. 545-554 ◽  
Author(s):  
VÉRONIQUE GIELEN ◽  
GILLES MAUDUIT ◽  
DANIEL SCHMITT ◽  
JEAN THIVOLET
Keyword(s):  
Monoclonal Antibodies ◽  
Human Skin ◽  
Hla Class I ◽  
Class I ◽  
Normal Human Skin ◽  
Normal Human

Anti-HLA antibodies interfere in the detection of soluble HLA class I molecules

1999 ◽  
Vol 60 (5) ◽  
pp. 414-423 ◽  
Author(s):  
Carin A Koelman ◽  
Wilma Ensink ◽  
Arend Mulder ◽  
Janneke Tanke ◽  
Ilias I.N Doxiadis ◽  
...  
Keyword(s):  
Hla Class I ◽  
Class I ◽  
Hla Antibodies ◽  
Hla Class I Molecules ◽  
Soluble Hla

scholarly journals Sex-Specific Differences in HLA Antibodies after Pneumococcal Vaccination in Kidney Transplant Recipients

Vaccines ◽  
2019 ◽  
Vol 7 (3) ◽  
pp. 84 ◽  
Author(s):  
Lindemann ◽  
Oesterreich ◽  
Wilde ◽  
Eisenberger ◽  
Muelling ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
De Novo ◽  
Pneumococcal Vaccination ◽  
Human Leukocyte ◽  
Hla Class I ◽  
Current Data ◽  
Class I ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Hla Antibodies

In transplant recipients vaccination against Streptococcus pneumoniae is recommended to reduce mortality from invasive pneumococcal disease. It is still debated if vaccination in transplant recipients triggers alloresponses. Therefore, it was our aim to define if vaccination with Prevenar 13®, a 13-valent, conjugated pneumococcal vaccine (Pfizer, New York, NY, USA) that acts T cell dependently, induces human leukocyte antigen (HLA) antibodies in clinically stable kidney transplant recipients. Forty-seven patients were vaccinated once with Prevenar 13® and HLA antibodies were determined prior to vaccination and at month 1 and 12 thereafter. In parallel, pneumococcal IgG antibodies were measured. Using Luminex™ Mixed Beads technology (One Lambda/Thermo Fisher, Canoga Park, CA, USA) we observed overall no change in HLA antibodies after vaccination. Pneumococcal antibodies increased significantly at month 1 (p < 0.0001) and remained elevated at month 12 (p < 0.005). A more detailed analysis of HLA antibodies showed that in 18 females HLA class I and II antibodies increased significantly at month 1 and 12 (p < 0.05); whereas in 29 males HLA class I and II antibodies tended to decrease. Using Luminex™ Single Antigen Beads assay, no de novo donor-specific HLA antibodies were detected after vaccination. In conclusion, the current data indicate that females may be more susceptible to the induction of (non-specific) HLA antibodies after vaccination.

scholarly journals Preclinical characterization of 1-7F9, a novel human anti–KIR receptor therapeutic antibody that augments natural killer–mediated killing of tumor cells

Blood ◽  
2009 ◽  
Vol 114 (13) ◽  
pp. 2667-2677 ◽  
Author(s):  
Francois Romagné ◽  
Pascale André ◽  
Pieter Spee ◽  
Stefan Zahn ◽  
Nicolas Anfossi ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Natural Killer ◽  
Tumor Cells ◽  
Nk Cell ◽  
Hla Class I ◽  
Therapeutic Antibody ◽  
Class I ◽  
Therapeutic Window ◽  
Target Cells ◽  
Term Survival

Abstract Inhibitory-cell killer immunoglobulin-like receptors (KIR) negatively regulate natural killer (NK) cell–mediated killing of HLA class I–expressing tumors. Lack of KIR-HLA class I interactions has been associated with potent NK-mediated antitumor efficacy and increased survival in acute myeloid leukemia (AML) patients upon haploidentical stem cell transplantation from KIR-mismatched donors. To exploit this pathway pharmacologically, we generated a fully human monoclonal antibody, 1-7F9, which cross-reacts with KIR2DL1, -2, and -3 receptors, and prevents their inhibitory signaling. The 1-7F9 monoclonal antibody augmented NK cell–mediated lysis of HLA-C–expressing tumor cells, including autologous AML blasts, but did not induce killing of normal peripheral blood mononuclear cells, suggesting a therapeutic window for preferential enhancement of NK-cell cytotoxicity against malignant target cells. Administration of 1-7F9 to KIR2DL3-transgenic mice resulted in dose-dependent rejection of HLA-Cw3–positive target cells. In an immunodeficient mouse model in which inoculation of human NK cells alone was unable to protect against lethal, autologous AML, preadministration of 1-7F9 resulted in long-term survival. These data show that 1-7F9 confers specific, stable blockade of KIR, boosting NK-mediated killing of HLA-matched AML blasts in vitro and in vivo, providing a preclinical basis for initiating phase 1 clinical trials with this candidate therapeutic antibody.

3.1-04 Production of monoclonal antibodies reactive with the new HLA class I molecules

1989 ◽  
Vol 26 ◽  
pp. 16
Author(s):  
D Geraghty ◽  
S Orcutt ◽  
T Staggs ◽  
J Hansen
Keyword(s):  
Monoclonal Antibodies ◽  
Hla Class I ◽  
Class I ◽  
Hla Class I Molecules
Sign in / Sign up

Export Citation Format

Share Document